Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab

Item

http://www.wikidata.org/entity/Q34483581

Q34483581

about

RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action Non-coding landscapes of colorectal cancer MicroRNAs and Chinese Medicinal Herbs: New Possibilities in Cancer Therapy Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: a systematic review and meta-analysis MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use MiRNAs and miRNA Polymorphisms Modify Drug Response Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial).MicroRNA binding site polymorphisms as biomarkers in cancer management and research.The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.MicroRNA-mediated regulation of KRAS in cancer MicroRNA as tools and therapeutics in lung cancer Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients.Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.MicroRNAs in colorectal cancer as markers and targets: Recent advances.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.MicroRNA dysregulation as a prognostic biomarker in colorectal cancer Early detection of colorectal cancer: from conventional methods to novel biomarkers.Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer.Noncoding RNA and colorectal cancer: its epigenetic role.Involvement of Non-coding RNAs in the Signaling Pathways of Colorectal Cancer.Polymorphisms in Non-coding RNA Genes and Their Targets Sites as Risk Factors of Sporadic Colorectal Cancer.Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.The role of microRNAs in cancer susceptibility.Dietary factors and microRNA-binding site polymorphisms in the IL13 gene: risk and prognosis analysis of colorectal cancer.KRAS polymorphisms are associated with survival of CRC in Chinese population.MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.

P2860

Q26773479-22A24D15-9983-4BFA-8120-7312A005C59A Q26778014-72D7F5BA-6EC4-447D-8FD1-90EFAAFE38D6 Q26797487-B8454BE2-53B4-463A-AB56-001E3B6140C0 Q26827474-1F8A497E-FC48-4CDB-8753-46D2EE6F2078 Q26861185-334206C0-0340-44B0-9DB9-B384DE5387A1 Q28079075-82ECD275-750F-4B6C-92DE-34FD8F92CC59 Q33855053-D766B341-2739-466E-BFF7-B1699E24CB7C Q34019040-7CA854C1-11C3-46BC-81AA-2D463F0ECD05 Q34134870-1F026E3D-5E83-4659-881F-04E5917013B5 Q34138308-C01FC593-2F62-4FB0-B83E-820373A551A2 Q34678120-4B51E3B7-87C4-4F8B-B8AB-B57A601A6185 Q35738706-836D25ED-8E9D-4C17-A44D-040A7FCAAEF8 Q35933551-287ACCB3-752C-4501-A703-61ACE78302B1 Q36000232-CB93AD88-A3CD-46C1-B04B-ED1387ED1756 Q37708024-30B1DB3E-AC98-4B7C-A44F-E5F67215A406 Q38118934-668671E3-0A2C-40F0-8488-CE27D1A66477 Q38222512-33FFB508-F168-467B-A263-549541ACB781 Q38262497-2384BBD4-0D05-49F2-8A1E-BAB7104D9188 Q38357717-8663B1E6-F473-4A78-858E-2BFEFBFB2400 Q38545768-33396B6E-2015-4B54-B05B-E3FE66BC6124 Q38859581-407D48E3-DE80-4BDE-AF6A-C34902BB9E40 Q38940586-83537A11-C2DA-4795-9A82-66895277ACEA Q38940602-607D5262-B35A-4342-8D07-7E9DD5F83100 Q39023377-E382A697-3315-410F-B8D6-C0693FB5E247 Q39558389-4D87424C-259B-4AD8-BEF1-4E976B076727 Q40188266-4937A910-DB15-40D1-A393-9CE19BB22F1D Q41170152-A2D64BD2-0D77-4F81-8BAB-401015A812D1 Q47630109-D62BAF90-9312-4EA0-9E23-A44A1A4802B1

P2860

Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab

Item

http://www.wikidata.org/entity/Q34483581

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu